Europe Equine Healthcare Market Size, Share & Trends Analysis Report By Product (Pharmaceuticals, Vaccine), By Indication (West Nile Virus, Tetanus), By Activity (Sports/Racing, Recreation), By Distribution Channel, By Country, And Segment Forecasts, 2025
Description
Europe Equine Healthcare Market Summary
The Europe equine healthcare market size was estimated at USD 1.00 billion in 2024 and is projected to reach USD 1.90 billion by 2033, growing at a CAGR of 7.57% from 2025 to 2033. The market is witnessing growth driven by the growing equine population and economic value, rising veterinarian guidance for preventive care, and increasing adoption of insurance and welfare programs.
The growing equine population within countries such as Germany, France, and the UK is creating opportunities for advanced veterinary care for the development of pharmaceuticals, vaccines, diagnostics, or services. According to the European Commission report, the equine population in the European Union (EU) is estimated to be approximately 6 million, with 429,800 horses in the UK. This rising equine population is driving significant growth opportunities in Europe’s equine healthcare market, fostering innovation across pharmaceuticals, vaccines, diagnostics, and veterinary services.
Some of the countries in Europe, such as the UK, France, and Ireland, are continuously involved in horse breeding and recreational or sports activities. Hence, horses are of great economic value in the category of companion animals. Their high economic importance drives the market for larger investment in veterinary care, advanced therapeutics, and specialized hospital services. For instance, in March 2024, Scandinavian ChemoTech’s Animal Care secured a USD 52k order from Europe’s leading equine clinic, EquiTom (Belgium), adopting vetIQure TSE technology after successful sarcoid treatments, enhancing innovation and patient outcomes in equine healthcare. As a result, the need for efficient healthcare solutions, including pharmaceuticals, vaccines, diagnostic tools, and reproductive management products, continues to expand across European equine markets.
Rising veterinarian guidance for preventive care is one of the drivers of the European equine healthcare market. With increasing awareness of equine welfare, veterinarians are emphasizing regular check-ups, vaccinations, deworming, and nutritional management to reduce the incidence of costly diseases. Preventive protocols help owners maintain peak equine performance, minimize risks of infectious outbreaks, and improve long-term health outcomes. In Europe, structured veterinary programs and educational campaigns encourage horse owners to adopt proactive healthcare measures rather than reactive treatment. For instance, in November 2022, British Equestrian launched Equine Health Week with vet-led education, daily disease awareness and the release of new EIDAG (Equine Infectious Diseases Advisory Group) guidance to reduce equine infectious disease risks. In addition, in March 2023, CANTER, launched to combat equine antiparasitic resistance, uniting veterinarians, pharmaceutical companies, diagnostic providers, and policymakers to promote sustainable parasite control and safeguard horse health and welfare. This shift enhances animal well-being and fuels demand for vaccines, supplements, and diagnostic services, boosting the industry.
Europe Equine Healthcare Market Report Segmentation
This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Europe equine healthcare market report based on product, indication, activity, distribution channel, and country:
The Europe equine healthcare market size was estimated at USD 1.00 billion in 2024 and is projected to reach USD 1.90 billion by 2033, growing at a CAGR of 7.57% from 2025 to 2033. The market is witnessing growth driven by the growing equine population and economic value, rising veterinarian guidance for preventive care, and increasing adoption of insurance and welfare programs.
The growing equine population within countries such as Germany, France, and the UK is creating opportunities for advanced veterinary care for the development of pharmaceuticals, vaccines, diagnostics, or services. According to the European Commission report, the equine population in the European Union (EU) is estimated to be approximately 6 million, with 429,800 horses in the UK. This rising equine population is driving significant growth opportunities in Europe’s equine healthcare market, fostering innovation across pharmaceuticals, vaccines, diagnostics, and veterinary services.
Some of the countries in Europe, such as the UK, France, and Ireland, are continuously involved in horse breeding and recreational or sports activities. Hence, horses are of great economic value in the category of companion animals. Their high economic importance drives the market for larger investment in veterinary care, advanced therapeutics, and specialized hospital services. For instance, in March 2024, Scandinavian ChemoTech’s Animal Care secured a USD 52k order from Europe’s leading equine clinic, EquiTom (Belgium), adopting vetIQure TSE technology after successful sarcoid treatments, enhancing innovation and patient outcomes in equine healthcare. As a result, the need for efficient healthcare solutions, including pharmaceuticals, vaccines, diagnostic tools, and reproductive management products, continues to expand across European equine markets.
Rising veterinarian guidance for preventive care is one of the drivers of the European equine healthcare market. With increasing awareness of equine welfare, veterinarians are emphasizing regular check-ups, vaccinations, deworming, and nutritional management to reduce the incidence of costly diseases. Preventive protocols help owners maintain peak equine performance, minimize risks of infectious outbreaks, and improve long-term health outcomes. In Europe, structured veterinary programs and educational campaigns encourage horse owners to adopt proactive healthcare measures rather than reactive treatment. For instance, in November 2022, British Equestrian launched Equine Health Week with vet-led education, daily disease awareness and the release of new EIDAG (Equine Infectious Diseases Advisory Group) guidance to reduce equine infectious disease risks. In addition, in March 2023, CANTER, launched to combat equine antiparasitic resistance, uniting veterinarians, pharmaceutical companies, diagnostic providers, and policymakers to promote sustainable parasite control and safeguard horse health and welfare. This shift enhances animal well-being and fuels demand for vaccines, supplements, and diagnostic services, boosting the industry.
Europe Equine Healthcare Market Report Segmentation
This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Europe equine healthcare market report based on product, indication, activity, distribution channel, and country:
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Pharmaceuticals
- Parasiticides
- Anti-infectives
- Anti-inflammatory & Analgesics
- Other Pharmaceuticals
- Vaccines
- Medicinal Feed Additives
- Orthobiologics
- Diagnostics
- Diagnostic Test Kits
- Diagnostics Equipment
- Software & Services
- Practice Management Software
- Imaging Software
- Telehealth Software
- Other Software & Services
- Others
- Indication Outlook (Revenue, USD Million, 2021 - 2033)
- Musculoskeletal Disorders
- Parasitic Infections
- Equine Herpes Virus
- Equine Viral Arteritis (EVA)
- Equine Influenza
- West Nile Virus
- Tetanus
- Other Indications
- Activity Outlook (Revenue, USD Million, 2021 - 2033)
- Sports/ Racing
- Recreation
- Other Activities
- Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Veterinary Hospitals & Clinics
- E-commerce
- Equestrian Facilities
- Other Channels
- Country Outlook (Revenue, USD Million, 2021 - 2033)
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Norway
- Denmark
- Netherlands
- Russia
- Switzerland
Table of Contents
180 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Indication
- 1.2.3. Activity
- 1.2.4. Distribution Channel
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR’s Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
- 1.5. Information/Data Analysis
- 1.5.1. Data Analysis Models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Model 1 Analysis
- 1.7.2. Model 2 Analysis
- 1.7.3. Model 3 Analysis
- 1.8. List of Secondary Sources
- 1.9. List Of Abbreviations
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
- Chapter 3. Market Variable Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary/Related Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Growing Equine Population And Economic Value
- 3.2.1.2. Rising Veterinarian Guidance For Preventive Care
- 3.2.1.3. Increasing Adoption Of Insurance And Welfare Programs
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. High Cost of Advanced Equine Healthcare Solutions
- 3.2.3. Market Opportunity Analysis
- 3.2.4. Market Challenge Analysis
- 3.3. Technology Landscape
- 3.4. Pricing Model Analysis
- 3.5. Estimated Equine Population by country, 2024
- 3.6. Market Analysis Tools
- 3.6.1. Porter’s Five Forces Analysis
- 3.6.2. PESTEL by SWOT Analysis
- Chapter 4. Europe Equine Healthcare Market: Product Estimates & Trend Analysis
- 4.1. Europe Equine Healthcare Market, By Product: Segment Dashboard
- 4.2. Europe Equine Healthcare Market, By Product Movement Analysis
- 4.3. Europe Equine Healthcare Market Estimates & Forecasts, by Product, 2021 to 2033 (USD Million)
- 4.4. Pharmaceuticals
- 4.4.1. Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 4.4.2. Parasiticides
- 4.4.2.1. Parasiticides Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 4.4.3. Anti-infectives
- 4.4.3.1. Anti-infectives Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 4.4.4. Anti-inflammatory & Analgesics
- 4.4.4.1. Anti-inflammatory & Analgesics Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 4.4.5. Other Pharmaceuticals
- 4.4.5.1. Other Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 4.5. Vaccines
- 4.5.1. Vaccines Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 4.6. Medicinal Feed Additives
- 4.6.1. Medicinal Feed Additives Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 4.7. Orthobiologics
- 4.7.1. Orthobiologics Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 4.8. Diagnostics
- 4.8.1. Diagnostics Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 4.8.2. Diagnostic Test Kits
- 4.8.2.1. Diagnostic Test Kits Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 4.8.3. Diagnostics Equipments
- 4.8.3.1. Diagnostics Equipments Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 4.9. Software & Services
- 4.9.1. Software & Services Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 4.9.2. Practice Management Software
- 4.9.2.1. Practice Management Software Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 4.9.3. Imaging Software
- 4.9.3.1. Imaging Software Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 4.9.4. Telehealth Software
- 4.9.4.1. Telehealth Software Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 4.9.5. Other Software & Services
- 4.9.5.1. Other Software & Services Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 4.10. Others
- 4.10.1. Others Market Estimates and Forecasts, 2021 - 2033(USD Million)
- Chapter 5. Europe Equine Healthcare Market: Indication Estimates & Trend Analysis
- 5.1. Europe Equine Healthcare Market, By Indication: Segment Dashboard
- 5.2. Europe Equine Healthcare Market, By Indication Movement Analysis
- 5.3. Europe Equine Healthcare Market Estimates & Forecasts, by Indication, 2021 to 2033 (USD Million)
- 5.4. Musculoskeletal Disorders
- 5.4.1. Musculoskeletal Disorders Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 5.5. Parasitic Infections
- 5.5.1. Parasitic Infections Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 5.6. Equine Herpes Virus
- 5.6.1. Equine Herpes Virus Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 5.7. Equine Viral Arteritis (EVA)
- 5.7.1. Equine Viral Arteritis (EVA) Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 5.8. Equine Influenza
- 5.8.1. Equine Influenza Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 5.9. West Nile Virus
- 5.9.1. West Nile Virus Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 5.10. Tetanus
- 5.10.1. Tetanus Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 5.11. Other Indications
- 5.11.1. Other Indications Market Estimates and Forecasts, 2021 - 2033(USD Million)
- Chapter 6. Europe Equine Healthcare Market: By Activity Estimates & Trend Analysis
- 6.1. Europe Equine Healthcare Market, By Activity: Segment Dashboard
- 6.2. Europe Equine Healthcare Market, By Activity Movement Analysis
- 6.3. Europe Equine Healthcare Market Estimates & Forecasts, by Activity, 2021 to 2033 (USD Million)
- 6.3.1. Sports/ Racing
- 6.3.1.1. Sports/ Racing Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 6.3.2. Recreation
- 6.3.2.1. Recreation Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 6.3.3. Others
- 6.3.3.1. Others Market Estimates and Forecasts, 2021 - 2033(USD Million)
- Chapter 7. Europe Equine Healthcare Market: By Distribution Channel Estimates & Trend Analysis
- 7.1. Europe Equine Healthcare Market, By Distribution Channel: Segment Dashboard
- 7.2. Europe Equine Healthcare Market, By Distribution Channel Movement Analysis
- 7.3. Europe Equine Healthcare Market Estimates & Forecasts, by Distribution Channel, 2021 to 2033 (USD Million)
- 7.3.1. Veterinary Hospitals & Clinics
- 7.3.1.1. Veterinary Hospitals & Clinics Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 7.3.2. E-commerce
- 7.3.2.1. E-commerce Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 7.3.3. Equestrian Facilities
- 7.3.3.1. Equestrian Facilities Market Estimates and Forecasts, 2021 - 2033(USD Million)
- 7.3.4. Others
- 7.3.4.1. Others Market Estimates and Forecasts, 2021 - 2033(USD Million)
- Chapter 8. Europe Equine Healthcare Market: By Country Estimates & Trend Analysis
- 8.1. Country Market Dashboard
- 8.2. Country Market Share Analysis, 2024 & 2033
- 8.3. Europe
- 8.3.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.2. UK
- 8.3.2.1. Key Country Dynamics
- 8.3.2.2. Competitive Scenario
- 8.3.2.3. Regulatory Framework
- 8.3.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.3. Germany
- 8.3.3.1. Key Country Dynamics
- 8.3.3.2. Competitive Scenario
- 8.3.3.3. Regulatory Framework
- 8.3.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.4. France
- 8.3.4.1. Key Country Dynamics
- 8.3.4.2. Competitive Scenario
- 8.3.4.3. Regulatory Framework
- 8.3.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.5. Italy
- 8.3.5.1. Key Country Dynamics
- 8.3.5.2. Competitive Scenario
- 8.3.5.3. Regulatory Framework
- 8.3.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.6. Spain
- 8.3.6.1. Key Country Dynamics
- 8.3.6.2. Competitive Scenario
- 8.3.6.3. Regulatory Framework
- 8.3.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.7. Denmark
- 8.3.7.1. Key Country Dynamics
- 8.3.7.2. Competitive Scenario
- 8.3.7.3. Regulatory Framework
- 8.3.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.8. Sweden
- 8.3.8.1. Key Country Dynamics
- 8.3.8.2. Competitive Scenario
- 8.3.8.3. Regulatory Framework
- 8.3.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.9. Norway
- 8.3.9.1. Key Country Dynamics
- 8.3.9.2. Competitive Scenario
- 8.3.9.3. Regulatory Framework
- 8.3.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.10. Netherlands
- 8.3.10.1. Key Country Dynamics
- 8.3.10.2. Competitive Scenario
- 8.3.10.3. Regulatory Framework
- 8.3.10.4. Netherlands Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.11. Russia
- 8.3.11.1. Key Country Dynamics
- 8.3.11.2. Competitive Scenario
- 8.3.11.3. Regulatory Framework
- 8.3.11.4. Russia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.12. Switzerland
- 8.3.12.1. Key Country Dynamics
- 8.3.12.2. Competitive Scenario
- 8.3.12.3. Regulatory Framework
- 8.3.12.4. Switzerland Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 9. Competitive Landscape
- 9.1. Market Participant Categorization
- 9.1.1. Market Leaders
- 9.1.2. Emerging Players
- 9.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
- 9.3. Company Profiles
- 9.3.1. Boehringer Ingelheim International GmbH.
- 9.3.1.1. Participant’s Overview
- 9.3.1.2. Financial Performance
- 9.3.1.3. Product/Service Benchmarking
- 9.3.1.4. Strategic Initiatives
- 9.3.2. Dechra
- 9.3.2.1. Participant’s Overview
- 9.3.2.2. Financial Performance
- 9.3.2.3. Product/Service Benchmarking
- 9.3.2.4. Strategic Initiatives
- 9.3.3. Ceva Sante Animale
- 9.3.3.1. Participant’s Overview
- 9.3.3.2. Financial Performance
- 9.3.3.3. Product/Service Benchmarking
- 9.3.3.4. Strategic Initiatives
- 9.3.4. Esaote S.p.A
- 9.3.4.1. Participant’s Overview
- 9.3.4.2. Financial Performance
- 9.3.4.3. Product/Service Benchmarking
- 9.3.4.4. Strategic Initiatives
- 9.3.5. AVANTEA
- 9.3.5.1. Participant’s Overview
- 9.3.5.2. Financial Performance
- 9.3.5.3. Product/Service Benchmarking
- 9.3.5.4. Strategic Initiatives
- 9.3.6. Equistro
- 9.3.6.1. Participant’s Overview
- 9.3.6.2. Financial Performance
- 9.3.6.3. Product/Service Benchmarking
- 9.3.6.4. Strategic Initiatives
- 9.3.7. Intervacc
- 9.3.7.1. Participant’s Overview
- 9.3.7.2. Financial Performance
- 9.3.7.3. Product/Service Benchmarking
- 9.3.7.4. Strategic Initiatives
- 9.3.8. HIPRA
- 9.3.8.1. Participant’s Overview
- 9.3.8.2. Financial Performance
- 9.3.8.3. Product/Service Benchmarking
- 9.3.8.4. Strategic Initiatives
- 9.3.9. Hallmarq Veterinary Imaging
- 9.3.9.1. Participant’s Overview
- 9.3.9.2. Financial Performance
- 9.3.9.3. Product/Service Benchmarking
- 9.3.9.4. Strategic Initiatives
- 9.3.10. Virbac
- 9.3.10.1. Participant’s Overview
- 9.3.10.2. Financial Performance
- 9.3.10.3. Product/Service Benchmarking
- 9.3.10.4. Strategic Initiatives
- 9.3.11. Norbrook
- 9.3.11.1. Participant’s Overview
- 9.3.11.2. Financial Performance
- 9.3.11.3. Product/Service Benchmarking
- 9.3.11.4. Strategic Initiatives
- 9.3.12. Strategy Mapping
- 9.3.13. Mergers & Acquisitions
- 9.3.14. Partnerships & Collaborations
- 9.3.15. Product launch
- 9.3.16. Others
- 9.4. List of other key players
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.